Information Provided By: 
Fly News Breaks for June 18, 2015
OVAS
Jun 18, 2015 | 08:27 EDT
After an additional doctor offering OvaScience's AUGMENT presented data, Oppenheimer says that the data indicates that AUGMENT does improve fertility rates in difficult-to-treat patients. The firm says that the 5% drop in the stock yesterday was either due to confusion surrounding OvaScience's 1,000 AUGMENT cycles guidance or based on differing expectations for the treated patient population. The firm reports that its checks with consultants indicate that the data was positive, and it keeps a $60 price target and Outperform rating on the shares.
News For OVAS From the Last 2 Days
There are no results for your query OVAS
